The Development of the Model Mice Having the System that Easily Measuring their Pancreatic Islet Beta Cell Mass

为了量化胰岛β细胞质量，我们试图开发一种非侵入性的、易于测量的系统。我们设计了一个β细胞模型，它结构性地分泌一个人造报告分子，反映用常规方法测量的β细胞质量。首先，我们构建了三种类型的人工融合蛋白。一种是人白蛋白信号序列与人C肽的融合(Alb-HC)，另一种是小鼠IgK信号序列与人C肽的融合(hCPR串联)，另一种是YFP的cDNA(hCPR/YFP)。我们已经确定了这些蛋白在培养的细胞系(Cos7，HEK293)外的表达和分泌，这意味着这些信号肽在体内扮演着分泌信号的角色。此外，我们还可以用人C-肽酶联免疫吸附试验试剂盒检测和检测这些融合蛋白，这些报告分子显然很容易测量。作为进一步的研究，我们将这些报告导入MIN6细胞和小鼠β细胞系，并证明其在其中的表达和分泌。重要的是要确认这些记者的分泌物是否构成。我们必须独立于几种条件(葡萄糖刺激等)来确定这些记者分泌的变化。这样我们就可以使用这些记者来计算β细胞的质量。在建立了导入这些融合基因的转基因小鼠后，我们正在将这些小鼠与其他糖尿病小鼠杂交。这些杂交小鼠将表现出β细胞团的变化，直到糖尿病发作。随着糖尿病发病或进展机制的阐明，这种非侵入性的β细胞质量定量系统将有助于开发抑制β细胞质量减少的新药或促进β细胞再生治疗的发展。

To quantify the islet beta cell mass, we tried to develop the noninvasive and easily measurable system. We designed a beta cell model, which constitutively secrete an artificial reporter molecule, reflecting the beta cell mass, to be measured with conventional methods. First of all, we have constructed three types of artificial fusion proteins. One has the human albumin signal sequence with the human C-peptide (Alb-hc), another two types of constructs both have the mice IgK signal sequence fused with human C-peptide cDNA (hCPR tandem) while the one has also YFP cDNA (hCPR/YFP). We have determined those proteins expression and secretion outside of cultured cell lines (Cos7, HEK293), meaning these signal peptides play the role as the secreting signal in vivo. Besides we could detect and measure those fusion proteins with the human C-peptide ELISA kit, these reporter molecules are apparently easy to be measured.As the further investigation, we will import those reporters into MIN6 cells, mouse beta cell line, and prove those expression in it and secretion. It is important to confirm whether those reporters secretion is constitutive or not. We have to determine the alteration of those reporters secretion independent of several conditions (glucose stimulation etc.) so that we will be able to use these reporters to calculate beta cell mass.After establishing transgenic mice imported those fusion genes, we are making hybrid mice between these mice and other diabetic mice. These hybrid mice will demonstrate the alteration of beta cell mass till the onset of diabetes mellitus. Along with the elucidation of the mechanism of the diabetes onset or progression, this noninvasive beta cell mass quantifying system will contribute to developing the new drugs to inhibit beta cell mass reduction or to the advancing of beta cell regenerative therapy.